Navigation Links
GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results
Date:11/19/2013

LONDON, Nov. 19, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announces its preliminary results for the fourth quarter and the year ended 30 September 2013.  

2013 HIGHLIGHTS:

  • Initial public offering on the NASDAQ Global Market completed in May 2013 raising total net proceeds before expenses of $30.7m (£19.8m)
  • Two U.S.-targeted Sativex® Phase 3 pivotal programs advanced in 2013
  • Cancer Pain: two pivotal Sativex Phase 3 trials in recruitment
  • First Phase 3 top-line results expected in H2 2014
  • Data intended to lead to a New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA)
  • Multiple Sclerosis (MS): Phase 3 Investigational New Drug (IND) application opened with the FDA for Sativex in the treatment of MS spasticity
  • Special Protocol Assessment (SPA) to be requested prior to anticipated start of Phase 3 trial in 2014
  • All Sativex Phase 3 clinical trials targeted at FDA approval are fully funded by U.S. partner, Otsuka
  • Sativex U.S. patent position further strengthened through two additional U.S. Notices of Allowance
  • Sativex now approved in 22 countries (ex-U.S) as a treatment for MS spasticity
  • In-market sales by partners increased by 25%
  • Commercial launch in Italy in July 2013
  • Germany pricing agreement reached in September 2013
  • Recommendation for approval in France in October 2013
  • On-going commercial launches in planning over next 12 months
  • New Sativex data presented at ECTRIMS in October 2013
  • Expansion of epilepsy research program through commencement of a new orphan pediatric epilepsy program for Epidiolex® (
    '/>"/>

  • SOURCE GW Pharmaceuticals plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
    2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
    3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
    4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
    5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
    6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
    7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
    8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
    10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
    11. Avanir Pharmaceuticals To Present at Three Conferences In May
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... Aug. 20, 2014 The National Necrotizing Fasciitis Foundation ... has been successfully treated for a life threatening form ... Anibal R. Gauto , Medical Director of Inpatient Wound Care ... Center in Rancho Mirage, California . ... Dr. John Crew at Seton Hospital in ...
    (Date:8/20/2014)... , Aug. 20, 2014 Research and Markets ... of Pralmorelin" report to their offering. ... comprehensive data on Pralmorelin globally and regionally ( Europe ... America , Latin America etc.). ... This report focuses on three primary areas; manufacture ...
    (Date:8/20/2014)... Research and Markets has ... Wound Care and Closure Market (Types, Applications, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, ... to their offering. The new ... market (types, applications, end user and geography) - ...
    Breaking Medicine Technology:Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 2Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 3Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 4Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 5Rancho Mirage, California Physician Saves Casino Worker from Deadly 'Flesh Eating Disease' 6Global Market Report of Pralmorelin 2Global Advanced Wound Care and Closure Market (Types, Applications, End User and Geography) - Forecast to 2020 2
    (Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
    (Date:8/20/2014)... common approach to treating kidney failure by removing waste ... for people who suddenly developed the condition, in an ... School of Medicine. , Their findings, published online in ... an aggressive method that is standardly used for people ... benefit to the patient. , "Our findings question the ...
    (Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
    (Date:8/20/2014)... 20, 2014 The non-small cell lung ... in the offing across the top 8 developed nations, ... to around USD 8 billion by 2020-end, posting a ... is projected to be driven by innovative therapies entering ... lacking efficient treatment, unlike the non-squamous segment. Thus, patients ...
    (Date:8/20/2014)... CA (PRWEB) August 20, 2014 The main ... 12 per diode panel band perfect spectrum that encompasses the ... most likely to use during photosynthesis. A key point ... is that they almost exclusively reside between 440-480 on the ... the red side of the spectrum. The KIND LED K3 ...
    Breaking Medicine News(10 mins):Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 2Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 3Health News:Top 8 Developed Nations NSCLC Market to Grow at CAGR of 6.6% Through 2020, Says GBI Research in Its Report Published at MarketPublishers.com 4Health News:Cheap LED Grow Lights Are Quickly Being Replaced by Premium Grow Lights 2
    ... ... 18 million Americans suffer from heavy snoring, but don’t realize it,s likely a tell-tale sign ... ... Americans suffer from heavy snoring, but don’t realize it may actually be a tell-tale sign ...
    ... 16 The 15th Annual National Ergonomics Conference ... - 20, will focus on the importance of workplace ergonomics ... topics of return on investment, the aging workforce, and safety ... offices and call centers, industrial, lab, healthcare, and uncontrolled environments ...
    ... It was found less effective than extended-release niacin, or ... new study raises more questions about ezetimibe (Zetia), a ... statins to lower LDL, or "bad," cholesterol. , The ... June after it was discovered that LDL-cholesterol-lowering Zetia was ...
    ... modern medicine finds a way to treat a medical condition, ... also have to find ways to get that treatment into ... research from North Carolina State University shows that much more ... hemophilia patients in the developing world, and that the current ...
    ... SINGAPORE, Nov. 16 /PRNewswire-Asia/ -- Retail sales ... in the first half of 2009 with,total consumption peaking in ... Contact Lens manufacturers. Positive sales,data showing a growth of 14% ... economic recovery that is being led by consumers spending. , ...
    ... of ketamine users has been published online today in ... Special K) use increasing faster than any other drug ... showing the consequences of repeated ketamine use provides valuable ... the study, researchers from University College London followed 150 ...
    Cached Medicine News:Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 2Health News:Heavy Snoring Linked To Potentially Life-Threatening Conditions 3Health News:2009 National Ergonomics Conference Opens in Las Vegas November 17 With Hundreds of Industry Leaders in Attendance 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 2Health News:Study Raises New Questions About Cholesterol Drug Zetia 3Health News:Research highlights need to address hemophilia in developing world 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 2Health News:GfK Asia Reports: Malaysian Contact Lens Market Sees Strong Recovery in Second Half of 2009 3Health News:First ever large-scale study of ketamine users published 2
    ... UltraClean Agarose, Molecular Biology Grade, ... separation of nucleic acids. It ... DNA fragments from 0.2 to ... UltraClean Agarose is tested and ...
    Inquire...
    ... Agarose 1000 is specifically formulated for high ... fragments <1000 bp. This standard melting temperature ... little as 10 bp difference in size. ... strong gel structure for better handling and ...
    High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2....
    Medicine Products: